Kyverna Therapeutics Unveils Detailed Positive Clinical Data for Miv-cel in SPS and gMG
KYTX has more than doubled off its 52-week low of $1.82 on elevated volume (2.4× avg).
Summary
Kyverna Therapeutics filed an 8-K furnishing presentation slides that detail highly positive clinical trial results for its miv-cel therapy in Stiff Person Syndrome (SPS) and generalized Myasthenia Gravis (gMG), reinforcing its potential as a first-in-class autoimmune CAR T treatment.
Key Events · Product Development and Regulatory · KYTX
-
SPS Registrational Trial Success
Miv-cel met its primary endpoint in the KYSA-8 registrational trial for Stiff Person Syndrome (SPS), showing a 46% median improvement in the Timed 25-Foot Walk (T25FW) at Week 16 (p=0.0003) and 100% of patients remaining free of immunotherapies.
-
gMG Phase 2 Data Reinforcement
Longer-term follow-up data from the KYSA-6 Phase 2 trial for generalized Myasthenia Gravis (gMG) demonstrated robust and sustained reductions in MG-ADL and QMG scores out to 52 weeks, with 100% of patients achieving clinically meaningful responses and high rates of immunotherapy-free remission.
-
Strong Safety Profile
Miv-cel exhibited a well-tolerated safety profile across both trials, with no high-grade Cytokine Release Syndrome (CRS) or Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) observed.
-
Advancing Pipeline
The positive data supports Kyverna's preparations for a Biologics License Application (BLA) submission for SPS and the ongoing advancement of its Phase 3 gMG trial, positioning miv-cel as a potential first-in-class autoimmune CAR T therapy.
Analysis · KYTX · Life Sciences
This 8-K provides the comprehensive clinical data supporting the positive top-line results for miv-cel in both the registrational KYSA-8 trial for Stiff Person Syndrome (SPS) and the Phase 2 KYSA-6 trial for generalized Myasthenia Gravis (gMG), which were initially announced on April 20 and April 21, 2026. The detailed presentation highlights that miv-cel met its primary endpoint in SPS with significant improvements in mobility and disability, and demonstrated robust, sustained efficacy in gMG, including 100% clinically meaningful response and high rates of immunotherapy-free remission. The well-tolerated safety profile across both indications further strengthens the drug's profile, positioning Kyverna for a potential BLA submission for SPS and advancement of its Phase 3 gMG trial. This detailed disclosure provides investors with critical evidence of the drug's transformative potential in autoimmune diseases.
How filings like this one have moved
In the 30 days to Sep 17, 2026, 40.1% of the 372 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.60%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KYTX was trading at $10.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $586.9M. The 52-week trading range was $1.82 to $13.67. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.